Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.65 |
| ▸ | PARG | Q86W56 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4593787 | 0.88 | KDM4E (0.70) | KCNH2HIF1APARGKDM4EL3MBTL1 | |
| SCHEMBL20893358 | 0.88 | L3MBTL1 (0.61) | KCNH2HIF1APARGKDM4EL3MBTL1 | |
| SCHEMBL4629108 | 0.87 | PLK1 (0.54) | KCNH2HIF1APARGKDM4EL3MBTL1 | |
| SCHEMBL10897719 | 0.87 | PTGS2 (0.59) | KCNH2HIF1AKDM4EL3MBTL1AHR | |
| SCHEMBL1474090 | 0.87 | MEN1 (0.60) | HIF1APARGKDM4EAHRUSP2 | |
| SCHEMBL20893375 | 0.85 | MAPT (0.62) | HIF1APARGKDM4EL3MBTL1AHR | |
| SCHEMBL16732898 | 0.85 | KDM4E (0.62) | HIF1APARGKDM4EL3MBTL1AHR | |
| SCHEMBL20893393 | 0.85 | PLK1 (0.56) | KCNH2HIF1APARGKDM4EL3MBTL1 | |
| SCHEMBL788918 | 0.85 | KCNH2 (0.67) | KCNH2HIF1APARGKDM4EAHR | |
| SCHEMBL30136795 | 0.85 | MAPT (0.62) | HIF1APARGKDM4EL3MBTL1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641908-B | Five-membered heterocyclic [3,4-d ] pyridazinone compound, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-11-19 | — | — | CN | disclosed |
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-05-09 | — | — | US | disclosed |
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2019-05-09 | — | — | US | disclosed |
| EP-3470415-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-04-17 | — | — | EP | disclosed |
| EP-3470415-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2019-04-17 | — | — | EP | disclosed |
| CN-109641908-A | Five-ring heterocycles simultaneously [3,4-d] pyridazinone compound, preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2019-04-16 | — | — | CN | disclosed |
| CN-107417687-A | Five-ring heterocycles simultaneously [3,4 d] pyridazinone compound, its preparation method, pharmaceutical composition and its application | 中国科学院上海药物研究所 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017202343-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D]PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135818-A1 | 5-MEMBERED HETEROCYCLE FUSED WITH [3,4-D] PYRIDAZINONE, AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF | FGFR1, FGFR3, FGFR4 | KCNH2 1512/4885HIF1A 2686/4885PARG 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.